Chemomab Therapeutics Ltd. announced financial results for the full year and fourth quarter ended December 31, 2025, with net loss of $9.0 million for the year and cash position of $10.4 million providing runway through end of Q1 2027. The company highlighted successful FDA End-of-Phase 2 meeting alignment on a single Phase 3 trial pathway for nebokitug in PSC.
Key takeaways
FDA alignment on Phase 3 trial design for nebokitug in PSC with primary composite endpoint of clinical events, following End-of-Phase 2 meeting on February 19, 2025.
Cash, cash equivalents and short-term deposits of $10.4 million as of December 31, 2025, runway through end of Q1 2027.
Full year 2025 net loss of $9.0 million or less than $0.02 per Ordinary Share vs $13.9 million or $0.04 per share in 2024.
R&D expenses of $5.8 million for full year 2025 vs $11.3 million in 2024 due to Phase 2 completion.
Phase 2 SPRING trial results published December 2, 2025 in American Journal of Gastroenterology.
David M. Weiner appointed Interim Chief Medical Officer and Jack Lawler promoted to Chief Development Officer on April 15, 2025.